SEARCH RESULTS

286387 RESULTS

Heinz Hillen on Donanemab Data Anchors Upbeat AAIC

COMMENT These data are a big step forward toward effective treatment and prevention in AD. Together with results from previous clinically effective and ineffective amyloid-modulating antibodies and low molecular-weight compounds, we should now be positioned to ad

Oskar Hansson on Donanemab Data Anchors Upbeat AAIC

COMMENT It is remarkable that we now have several anti-amyloid therapies that have been proven to slow down the disease progression of Alzheimer’s disease when initiated in amyloid-positive patients with amnestic MCI or mild dementia. While the donanemab Phase 2

Give BACE Inhibitors a Second Chance?

CONFERENCE COVERAGE 2023-07-29 Conference Coverage Scientists once hoped that blocking β-secretase would slow or prevent Alzheimer’s disease. Then came the rude awakening. The inhibitors caused the very thing they were supposed to prevent—cognitive decline. Enthusiasm tanked. Pharmaceu

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE